Immatics (NASDAQ:IMTX – Get Free Report)’s share price rose 0.1% during trading on Thursday . The stock traded as high as $12.81 and last traded at $12.39. Approximately 367,406 shares were traded during mid-day trading, a decline of 26% from the average daily volume of 495,369 shares. The stock had previously closed at $12.38.
Analyst Ratings Changes
Separately, Mizuho raised their target price on Immatics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, May 16th.
Read Our Latest Research Report on IMTX
Immatics Stock Down 0.7 %
Immatics (NASDAQ:IMTX – Get Free Report) last issued its earnings results on Tuesday, May 14th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.70. The business had revenue of $32.87 million during the quarter, compared to analysts’ expectations of $17.76 million. Immatics had a negative return on equity of 29.36% and a negative net margin of 107.80%. Equities analysts forecast that Immatics will post -1.25 EPS for the current year.
Institutional Trading of Immatics
Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its holdings in shares of Immatics by 324.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company’s stock worth $16,310,000 after acquiring an additional 1,183,860 shares in the last quarter. RTW Investments LP raised its holdings in shares of Immatics by 75.7% during the fourth quarter. RTW Investments LP now owns 1,484,911 shares of the company’s stock worth $15,636,000 after acquiring an additional 639,911 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Immatics during the fourth quarter worth $22,113,000. Wasatch Advisors LP purchased a new stake in shares of Immatics during the first quarter worth $7,676,000. Finally, Wellington Management Group LLP raised its holdings in shares of Immatics by 13.3% during the fourth quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company’s stock worth $66,896,000 after acquiring an additional 747,772 shares in the last quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.
Immatics Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Featured Stories
- Five stocks we like better than Immatics
- What Does Downgrade Mean in Investing?
- Why Call Options Volume for These 2 Stocks Spiked Together
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- MarketBeat Week in Review – 7/22 – 7/26
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.